Apellis Has New Hope for Pegcetacoplan With Longer-Term Data
18-Month Results Could Vindicate Geographic Atrophy Program
Executive Summary
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
You may also be interested in...
Apellis Aims New Pegcetacoplan Data At Market, Not Regulators
The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.
November Gloom? US FDA’s Goal Dates Include Hard Calls On Ferring Rebyota, Y-mAbs’ Omblastys
November should see FDA action on what could be the first standardized fecal microbiota transplant product, rare cancer therapies from Y-mAbs and Spectrum, uniQure/CSL’s hemophilia B gene therapy and Provention Bio’s biologic to delay type 1 diabetes.
Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.